Emibetuzumab

Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type) . Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer[1].

Product Specifications

CAS Number

[1365287-97-3]

Product Name Alternative

LY2875358

UNSPSC

12352203

Target

C-Met/HGFR

Type

Inhibitory Antibodies

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/emibetuzumab.html

Purity

95.00

Solubility

10 mM in DMSO

Smiles

[Emibetuzumab]

Molecular Weight

(144.56 kDa)

References & Citations

[1]Liu L, et al. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth. Clin Cancer Res. 2014 Dec 1;20 (23) :6059-70.